+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blood Cancer Drugs Global Market Report 2020

  • ID: 4871546
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc
  • Bayer AG
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
Blood Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global blood cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the blood cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Blood Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Blood Cancer Type : Leukemia, Lymphoma, Myeloma 2) By Drugs: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
  • Companies Mentioned: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly,
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc
  • Bayer AG
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
1. Executive Summary

2. Blood Cancer Drugs Market Characteristics

3. Blood Cancer Drugs Market Size And Growth
3.1. Global Blood Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Blood Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Blood Cancer Drugs Market Segmentation
4.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Leukemia
  • Lymphoma
  • Myeloma
4.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Rituaxan/Mabthera (Rituximab)
  • Gleevac/Glivec (Imatinib)
  • Revlimid (Lenalidomide)
  • Velcade (Bortezomib)
  • Tasigna (Nilotinib)
  • Pomalyst (Pomalidomide)
  • Vidaza (Azacitidine)
  • Kyprolis (Carfilzomib)
  • Adcetris (Brentuximab Vedotin)
  • Others
5. Blood Cancer Drugs Market Regional And Country Analysis
5.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Blood Cancer Drugs Market
6.1. Asia-Pacific Blood Cancer Drugs Market Overview
6.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Blood Cancer Drugs Market
7.1. China Blood Cancer Drugs Market Overview
7.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Blood Cancer Drugs Market
8.1. India Blood Cancer Drugs Market Overview
8.2. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Blood Cancer Drugs Market
9.1. Japan Blood Cancer Drugs Market Overview
9.2. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Blood Cancer Drugs Market
10.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Blood Cancer Drugs Market
11.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Blood Cancer Drugs Market
12.1. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Blood Cancer Drugs Market
13.1. Western Europe Blood Cancer Drugs Market Overview
13.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Blood Cancer Drugs Market
14.1. UK Blood Cancer Drugs Market Overview
14.2. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Blood Cancer Drugs Market
15.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Blood Cancer Drugs Market
16.4. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Blood Cancer Drugs Market
17.1. Eastern Europe Blood Cancer Drugs Market Overview
17.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Blood Cancer Drugs Market
18.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Blood Cancer Drugs Market
19.1. North America Blood Cancer Drugs Market Overview
19.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Blood Cancer Drugs Market
20.1. USA Blood Cancer Drugs Market Overview
20.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Blood Cancer Drugs Market
21.1. South America Blood Cancer Drugs Market Overview
21.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Blood Cancer Drugs Market
22.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Blood Cancer Drugs Market
23.1. Middle East Blood Cancer Drugs Market Overview
23.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Blood Cancer Drugs Market
24.1. Africa Blood Cancer Drugs Market Overview
24.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Blood Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Blood Cancer Drugs Market Competitive Landscape
25.2. Blood Cancer Drugs Market Company Profiles
25.2.1. Amgen Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. AstraZeneca PLC
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bayer AG
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Celgene Corporation
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Eli Lilly
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Blood Cancer Drugs Market

27. Blood Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Blood Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Astellas Pharma Inc
  • Bayer AG
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others

The global blood cancer drugs market was valued at about $33 billion in 2018 and is expected to grow to $43.74 billion at a CAGR of 7.3% through 2022.

North America was the largest region in the blood cancer drugs market in 2018, followed by Europe. This region is expected to remain the largest during the next five years. The blood cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to 2018 Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases myeloma. Furthermore the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukemia in the United States and an estimated 68,000 deaths will result from blood cancer. According to national cancer institute, the estimated deaths due to blood cancer are expected to be around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.

Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials is also high as clinical trial phases involves huge investments. According to Tufts Center for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion in 2017. This cost has increased more than 10 folds, with the cost of bringing a new drug to the market being $320 million in 1990s. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo's leukemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.

In 2019, Eli Lilly, a US-based Pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers. The company focuses on building small molecule cancer drugs for genetically defined cancer patients. The company was founded in 2013 and is headquartered in Stamford, Connecticut, USA.

Major players in the market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly
Note: Product cover images may vary from those shown
4 of 5
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Ltd
  • F.Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc
  • GlaxoSmithKline Pharmaceuticals Ltd
  • Merck and Company
  • Roche Holding AG
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll